Holen Sie sich die Stockscreener-App
1.785
2.46%
-0.045
Schlusskurs vom Vortag:
$1.83
Offen:
$1.8359
24-Stunden-Volumen:
34,540
Relative Volume:
0.78
Marktkapitalisierung:
$18.16M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-17.93M
KGV:
-1.0085
EPS:
-1.77
Netto-Cashflow:
$-14.28M
1W Leistung:
-2.99%
1M Leistung:
-15.45%
6M Leistung:
-9.85%
1J Leistung:
+23.96%
1-Tages-Spanne:
$1.7296
$1.8359
1-Wochen-Bereich:
$1.7296
$2.08
52-Wochen-Spanne:
$1.35
$3.26
Cocrystal Pharma Inc Stock (COCP) Company Profile
Firmenname
Cocrystal Pharma Inc
Sektor
Branche
Telefon
(786) 459-1831
Adresse
19805 N. CREEK PARKWAY, BOTHELL, WA
Vergleichen Sie COCP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COCP
Cocrystal Pharma Inc
|
1.785 | 18.16M | 0 | -17.93M | -14.28M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Cocrystal Pharma Inc Stock (COCP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-07-08 | Eingeleitet | H.C. Wainwright | Buy |
Cocrystal Pharma Inc Aktie (COCP) Neueste Nachrichten
Athira Pharma (NASDAQ:ATHA) Stock Quotes, Forecast and News Summary - Benzinga
Global Influenza Vaccine Market is Projected to Cross USD 14 Billion Mark by 2032 | DelveInsight - The Malaysian Reserve
Cocrystal Pharma And 2 Other Promising US Penny Stocks To Watch - Simply Wall St
Honeywell International Inc’s (HON) Stock: A Long-Term Performance Analysis - The News Heater
An In-Depth Look at BP plc ADR’s (BP) Stock Performance - The News Heater
Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development - The Manila Times
Conduit's AI-Powered Drug Development Takes Major Leap: Real-Time Trial Dashboard Unveiled - StockTitan
Drugmakers prep for bird flu outbreak, despite continued low risk - PharmaVoice
Cocrystal Pharma Extends Phase 2a Influenza Drug Study Amid Lower Infection Rates, Stock Near 52-Week High - HPBL
Influenza Clinical and Non-Clinical Studies, Key Companies, - openPR
What is Northland Capmk’s Forecast for CECO FY2024 Earnings? - Defense World
HC Wainwright Forecasts Higher Earnings for Cocrystal Pharma - Defense World
Influenza Pipeline Insights, Clinical Trials Analysis, Emerging Therapies and Companies | DelveInsight - EIN News
**Cocrystal Pharma, Inc. Presents Corporate Update to Investment Community** - Defense World
Midday Market Movers: Biggest Stock Declines of the Day – Market - HPBL
Cocrystal Pharma Engages Investors with Limited Disclosure - TipRanks
Cocrystal Pharma Reports Positive Phase 1 Results with Oral Pan-Viral Protease Inhibitor CDI-988 for Norovirus and Coronavirus Infections - Defense World
COCP: Phase 2a Trial of CC-42344 Extended - Smartkarma
COCP: Phase 2a Trial of CC-42344 Extended… - Zacks Small Cap Research
Cocrystal Pharma Reports Positive Phase 1 Study Results - TipRanks
Cocrystal Pharma Reports Phase 1 Results with Oral, - GlobeNewswire
Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections - Yahoo Finance
NV5 Announces New Goal of $1.6 Billion in Revenues by 2028 - The Manila Times
Cocrystal to extend enrolment in Phase IIa influenza inhibitor trial - Yahoo Finance
CLS Holdings USA, Inc. Executes Agreement to Amend Convertible Debentures - Defense World
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Sees Large Growth in Short Interest - Defense World
BRC Inc. (NYSE: BRCC) Amends Credit Agreements and Enters into $40 Million Term Loan Facility - Defense World
A SPAC III Acquisition Corp Announces Agreement with HD Education Group Limited - Defense World
Supermarket Income REIT (OTCMKTS:SUPIF) Shares Up 0.7% – Should You Buy? - Defense World
Cornish Metals (LON:CUSN) Shares Up 1.1% – What’s Next? - Defense World
Greenwave Technology Solutions (NASDAQ:GWAV) Stock Price Down 3.9% – Here’s What Happened - Defense World
Cocrystal Pharma, Inc. to Extend Phase 2a Influenza Challenge Study with Oral PB2 Inhibitor CC-42344 - Marketscreener.com
Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide - Benzinga
Cocrystal Pharma Shares Drop 35% Following Phase 2a Study Extens - GuruFocus.com
Cocrystal Pharma Shares Drop 35% Following Phase 2a Study Extension Announcement - GuruFocus.com
Stock market news: Coeptis Therapeutics Holdings -96.03%, OptiNose -93.07% among biggest losers during mid day trading - Business Upturn
Cocrystal stock plunges 40% on influenza drug update - MSN
Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet - Benzinga
Cocrystal stock plunges 40% on influenza drug update (COCP:NASDAQ) - Seeking Alpha
US Stocks Open Higher; House Prices Increase In October - Benzinga
Equitable Holdings, Inc. (NYSE: EQH): Insider Trades, Institutional Moves, and Market Momentum - HPBL
Alexander, Inc. (NYSE: ALX): A Deep Dive into Rising Short Interest, Dividends, and Institutional Activity - HPBL
EQT Corporation: A Deep Dive into the Natural Gas Giant Performance and Market Insights – News - HPBL
Cocrystal Pharma Extends Enrollment for Influenza Study - TipRanks
Cocrystal Pharma Shares Fall After Flu-Treatment Study Is Extended - MarketWatch
Carter, Inc. Faces Growing Short Interest and Market Dynamics in December 2024 – News - HPBL
Canoo Downgraded by Stifel Amid Rising Liquidity Risks and Operational Challenges – News - HPBL
Wall Street holiday: When are Nasdaq, NYSE shut for trading on account of New year’s holiday- December 31 or January 1? | Stock Market News - Mint
Cocrystal Pharma extends trial due to low flu infection rate - Investing.com
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344 - GlobeNewswire
Finanzdaten der Cocrystal Pharma Inc-Aktie (COCP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.53%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):